andrew_nyc said:Almost every unanswerable question in these threads is unanswerable because three things changed in the same fortnight, and no amount of subsequent…
All true, with one condition: that curve is for people who reached the dose on schedule. Anyone who slowed the ladder for tolerability is on a different, flatter curve, and comparing yourself with the published mean will make you feel like a non-responder when you are not.
JessicaM_2024 said:Albumin binding above 99% is the whole reason weekly dosing works, and it is also why the trough matters more than the peak.
This is exactly what I could not find anywhere else.
andrew_nyc said:Almost every unanswerable question in these threads is unanswerable because three things changed in the same fortnight, and no amount of subsequent…
I will push back on the "any working dose is fine" framing. The maintenance evidence sits overwhelmingly at the top studied dose, and the extension data shows regain tracking dose reduction rather than tracking stopping. Holding low is reasonable; pretending it is evidentially equivalent is not.
Sigma-Aldrich — Research-Grade Standards
Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.
Shop Reference StandardsOne concrete data point for the thread. Give anything pharmacological four weeks before you judge it, and give anything measured weekly a four-point rolling average before you call it a trend.
Ask again with the specifics and you will get a better answer than this one.
Moderator note: a post naming a supplier has been edited. Discuss suppliers in the review sections, not here. Thread quality here is what the rules are for. Keep it up.